Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsResearch reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.
Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.
IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis
1.
Unified Neuro/Psych Residency Program: New Proposal.
2.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
3.
Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A
4.
Top 10 questions about breast cancer answered
5.
No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances
1.
The Importance of Corrected Calcium Levels in Managing Health Conditions
2.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
3.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
4.
Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders
5.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge